Starting Dose of Buspirone (Buspar)
The recommended starting dose of buspirone is 15 mg daily, typically divided as 7.5 mg twice daily. 1
Dosing Algorithm
Initial Dosing
- Start with 15 mg/day (7.5 mg twice daily) 1
- This is the FDA-approved initial dose for adults without hepatic impairment
- Take consistently either always with food or always without food, as food increases bioavailability approximately 2-fold 1, 2
Dose Titration
- Increase by 5 mg/day every 2-3 days as needed to achieve optimal therapeutic response 1
- Commonly employed effective doses in clinical trials: 20-30 mg/day in divided doses 1
- Maximum dose: 60 mg/day 1
Special Populations
Elderly patients (≥65 years):
- No dose adjustment required 1, 3
- Pharmacokinetics are not affected by age 1
- Safety and efficacy profiles similar to younger patients 3
Hepatic impairment:
- Contraindicated in severe hepatic impairment 1
- In hepatic impairment, Cmax and AUC increase 15-fold with half-life doubling 2
- Cannot be recommended for patients with severe hepatic or renal impairment 1
Renal impairment:
Important Clinical Considerations
Onset of Action
- May take 2-4 weeks to become effective 4
- This delayed onset is critical for patient counseling to prevent premature discontinuation
Food Effects
- Must be taken consistently with regard to food timing 1
- Food increases both Cmax and AUC by approximately 2-fold 1, 2
- Inconsistent administration can lead to variable plasma levels
Drug Interactions Requiring Dose Adjustment
When co-administered with potent CYP3A4 inhibitors (verapamil, diltiazem, erythromycin, itraconazole), buspirone plasma concentrations increase substantially 2
- Follow specific dose reduction recommendations per FDA labeling 1
MAOI Considerations
- Allow at least 14 days between discontinuing an MAOI and starting buspirone 1
- Allow at least 14 days after stopping buspirone before starting an MAOI 1
Common Pitfalls to Avoid
- Starting too high: The 15 mg/day starting dose is evidence-based; higher initial doses increase side effects without improving efficacy
- Inconsistent food timing: Variable bioavailability can lead to fluctuating therapeutic response
- Premature discontinuation: Patients must understand the 2-4 week delay in therapeutic effect
- Ignoring hepatic/renal function: Always assess liver and kidney function before initiating therapy
Maintenance Therapy
- Most patients successfully managed on 15-30 mg/day 5
- Long-term use (up to 52 weeks) showed no new safety concerns 5
- No withdrawal syndrome observed with abrupt discontinuation after >6 months of therapy 5
The evidence consistently supports 15 mg/day as the optimal starting dose, with systematic titration based on individual response rather than arbitrary higher initial dosing.